Program
MWX203
A development code. Also written as “MWX203 S1”, “MWX203 S2” and “MWX203 S3”.
Its studies are mostly in Dyslipidemias, led by Lepu Medical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lepu Medical | 22 open or running | phase 2since Sep 1, 2026 | Aug 24, 2026 | Feb 2028phase 2 · NCT07803822 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 24, 2026First study: phase 1 study in Healthy VolunteersFirst studyNCT07799025 · 54 enrolled · China
- Sep 1, 2026Phase 2 study in Mixed DyslipidemiaPhase 2 reachedNCT07803822 · 216 planned · China
Ahead
- Feb 2028Primary completion: phase 2 study in Mixed DyslipidemiaNCT07803822
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07803822Mixed Dyslipidemia · China | 2 | Recruiting | Feb 2028 | 216 |
| NCT07799025Healthy Volunteers · China | 1 | Active, not recruiting | Mar 7, 2026 | 54 |
How it is read
Names in the registry
- “MWX203”, 1 entry
- “MWX203 S1”, 1 entry
- “MWX203 S2”, 1 entry
- “MWX203 S3”, 1 entry
- “MWX203 S4”, 1 entry
Codes read as this program: MWX203.
Conditions, from the studies’ own filings
- Dyslipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.